Cargando…

Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force

BACKGROUND: Neuroblastoma is an embryonic tumour of the sympathetic nervous system, metastatic in half of the patients at diagnosis, with a high preponderance of osteomedullary disease, making accurate evaluation of metastatic sites and response to therapy challenging. Metaiodobenzylguanidine (mIBG)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matthay, K K, Shulkin, B, Ladenstein, R, Michon, J, Giammarile, F, Lewington, V, Pearson, A D J, Cohn, S L
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2010
Materias:	Guidelines
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2865749/ https://www.ncbi.nlm.nih.gov/pubmed/20424613 http://dx.doi.org/10.1038/sj.bjc.6605621

Ejemplares similares

Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project
por: Schleiermacher, G, et al.
Publicado: (2012)

International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee
por: Ambros, P F, et al.
Publicado: (2009)

(123)I-mIBG scintigraphy in neuroblastoma: development of a SIOPEN semi-quantitative reporting ,method by an international panel
por: Lewington, V., et al.
Publicado: (2016)

Identification of the Novel Methylated Genes' Signature to Predict Prognosis in INRG High-Risk Neuroblastomas
por: Liu, Zhichao, et al.
Publicado: (2021)

Retracted: Identification of the Novel Methylated Genes' Signature to Predict Prognosis in INRG High-Risk Neuroblastomas
por: Osteoporosis, Journal of
Publicado: (2022)

Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force
por: Beiske, K, et al.
Publicado: (2009)

(123)I metaiodobenzylguanidine (MIBG) uptake predicts early relapse of neuroblastoma using semi-quantitative SPECT/CT analysis
por: Kitamura, Yoshiyuki, et al.
Publicado: (2021)

Retrospective Analysis of INRG Clinical and Genomic Factors for 605 Neuroblastomas in Japan: A Report from the Japan Children’s Cancer Group Neuroblastoma Committee (JCCG-JNBSG) †
por: Ohira, Miki, et al.
Publicado: (2021)

Evaluation of iodine-123-labeled metaiodobenzylguanidine single-photon emission computed tomography/computed tomography based on the International Society of Pediatric Oncology Europe Neuroblastoma score in children with neuroblastoma
por: Zhou, Ziang, et al.
Publicado: (2023)

Analysis of quantitative [I-123] mIBG SPECT/CT in a phantom and in patients with neuroblastoma
por: Brady, Samuel L., et al.
Publicado: (2019)

Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group
por: DuBois, Steven G., et al.
Publicado: (2012)

Complete surgical resection improves outcome in INRG high-risk patients with localized neuroblastoma older than 18 months
por: Fischer, Janina, et al.
Publicado: (2017)

The role of (131)I-metaiodobenzylguanidine (MIBG) therapy in unresectable and compromising localised neuroblastoma
por: Schoot, Reineke A., et al.
Publicado: (2013)

Iodine-131 Metaiodobenzylguanidine Therapy for Neuroblastoma: Reports So Far and Future Perspective
por: Kayano, Daiki, et al.
Publicado: (2015)

The efficacy and safety of Iodine-131-metaiodobenzylguanidine therapy in patients with neuroblastoma: a meta-analysis
por: He, Huihui, et al.
Publicado: (2022)

SIOP‐PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in low‐ and middle‐income settings
por: Parikh, Nehal S., et al.
Publicado: (2015)

Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group
por: De Bernardi, B, et al.
Publicado: (2008)

I-131-Metaiodobenzylguanidine therapy with allogeneic cord blood stem cell transplantation for recurrent neuroblastoma
por: Sato, Yuya, et al.
Publicado: (2012)

Unusual Case of Neuroblastoma with Only Growth Plate Metastasis in Bilateral Lower Limbs on Metaiodobenzylguanidine Scintigraphy
por: Yadav, Naveen, et al.
Publicado: (2021)

(123)I‐Metaiodobenzylguanidine Myocardial Scintigraphy in Discriminating Degenerative Parkinsonisms
por: Catalan, Mauro, et al.
Publicado: (2021)

Neuroblastoma
por: Pearson, D.
Publicado: (1977)

(131)I-metaiodobenzylguanidine ((131)I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients
por: Garaventa, A, et al.
Publicado: (1999)

Autonomic disorders and myocardial 123I-metaiodobenzylguanidine scintigraphy in Huntington’s disease
por: Assante, Roberta, et al.
Publicado: (2020)

Toxicity of upfront (131)I-metaiodobenzylguanidine ((131)I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis
por: Bleeker, Gitta, et al.
Publicado: (2013)

Is there a role for retinoids to treat minimal residual disease in neuroblastoma?
por: Matthay, K K, et al.
Publicado: (2000)

I -123 metaiodobenzylguanidine imaging for predicting ventricular arrhythmia in heart failure patients
por: Zhou, Weihua, et al.
Publicado: (2013)

Thyroid function after diagnostic (123)I-metaiodobenzylguanidine in children with neuroblastic tumors
por: Clement, Sarah C., et al.
Publicado: (2022)

Impact of mediastinal, liver and lung (123)I-metaiodobenzylguanidine ((123)I-MIBG) washout on calculated (123)I-MIBG myocardial washout
por: Verberne, Hein J., et al.
Publicado: (2009)

Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study
por: Berbegall, Ana P., et al.
Publicado: (2018)

Complete remission of metastatic pheochromocytoma in (123)I-metaiodobenzylguanidine scintigraphy after a single session of (131)I-metaiodobenzylguanidine therapy: a case report
por: Sugino, Teruaki, et al.
Publicado: (2017)

How often and to what extent do admitted COVID-19 patients have signs of cardiac injury?
por: Habets, M. A. W., et al.
Publicado: (2021)

(123)I-Labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis
por: Noordzij, Walter, et al.
Publicado: (2012)

Uptake Index of (123)I-metaiodobenzylguanidine Myocardial Scintigraphy for Diagnosing Lewy Body Disease
por: Kamiya, Yoshito, et al.
Publicado: (2017)

Cardiac 123I-Metaiodobenzylguanidine (MIBG) Scintigraphy in Parkinson’s Disease: A Comprehensive Review
por: Pitton Rissardo, Jamir, et al.
Publicado: (2023)

Two Cases of Decreased (123)I-Metaiodobenzylguanidine Lung Uptake in Metaiodobenzylguanidine Scintigraphy While Taking Selective Serotonin Reuptake Inhibitor/Serotonin Noradrenaline Reuptake Inhibitor
por: Adaniya, Shinobu, et al.
Publicado: (2021)

EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides
por: Handkiewicz-Junak, Daria, et al.
Publicado: (2018)

Can cardiac iodine-123 metaiodobenzylguanidine imaging contribute to risk stratification in heart failure patients?
por: Bax, Jeroen J., et al.
Publicado: (2008)

The Potential Role of Iodine-123 Metaiodobenzylguanidine Imaging for Identifying Sustained Ventricular Tachycardia in Patients with Cardiomyopathy
por: Klein, Thomas, et al.
Publicado: (2013)

Cardiac (123)I-metaiodobenzylguanidine Scintigraphy in a Patient with Familial Parkinsonism with Parkin Gene Mutation
por: Kim, Young-Do, et al.
Publicado: (2010)

(123)I-Metaiodobenzylguanidine Myocardial Scintigraphy in Lewy Body-Related Disorders: A Literature Review
por: Chung, Eun Joo, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_sjg9s4etcb7bij9d4ked99i85h